Supplemental Figure 2. Validation of RBD target in B16F10 cells by delivery of RBD protein via Co/ZnO or CoFe/ZnO PMC nanoparticles increasing anticancer activity against B16F10 cells with %viability determined relative to untreated controls by MTT assay
Aims: To investigate the distribution, tolerance, and anticancer/antiviral activity of Zn-based physiometacomposites (PMCs). Methods: Manganese, iron, nickel and cobalt doped ZnO, ZnS or ZnSe were synthesized. Cell uptake, distribution into 3-D culture and mice, biochemical and chemotherapeutic activity were studied by fluorescence/bioluminescence, confocal microscopy, flow cytometry, viability, antitumor and virus titer assays. Results: Luminescence and inductively coupled plasma mass spectrometry analysis showed that nanoparticle distribution was liver>spleen>kidney>lung>brain, without tissue or blood pathology. Photophysical characterization as ex vivo tissue probes and LL37 peptide, antisense oligomer (ASO) or aptamer delivery targeting RAS/RBD. 25 µg/ml 48-hour treatment showed >98-99% cell viability, 3-D organoid uptake, 3-log inhibition of β-Galactosidase and porcine reproductive respiratory virus infection. Conclusions: Data support the preclinical development of PMCs for imaging and delivery targeting cancer and infectious disease.